Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
they just beat it up on the periphery.
ILT - I believe a few well informed posters such as Flip have been pointing out the risks and hype of CAR-T therapy for a while. So, a formal label requirement from a regulator certainly adds credence to what they have been saying here.
I would say follow the money for the Blair Institute and I suspect a substantial trail leads to BioNTech.
Sadly that is not onky true but very prevalent - one way for MMs like KG to set the price of securities to what they want it to be, aka what they value it.
That is welcome relief.
Color me cynical, but plenty of time left fir the last second pre-close slam.
The website going down would be the responsibility of IT and not LP, LG, Boynton, Bosch, or even DI - the people that are usually included in the term 'Management' on this board.
But does that 3 year window also include any clinical trials or i it just to 'identify and formulate' the drug/therapy? In the latter case, clinical trials will need to be added to the time frame to arrive at market availability.
And on what basis have you summarily dismissed Fliperr44's reasoning?
Last I heard he was at Regeneron.
So what is the process at this point? Does each party get additional time to respond to the other's filing before the magistrate judge makes another recommendation or is it now in the hands of the magistrate judge to make a recommendation?
You do know that AF is Cramer's buddy and AF's bashing of NWBO started when he worked for Cramer before moving to Stat News?
From the article:
In a recent Phase 3 prospective externally controlled non-randomized trial, the overall survival rate (OS) of GBM patients who received treatment with tumor lysate-loaded DC vaccine (DCVax-L) in addition to the standard of care (SOC) was compared to that of externally matched patients who underwent SOC alone over the same period [68]. The study revealed that the inclusion of DCVax-L along with SOC led to a significant and clinically meaningful extension of survival among GBM patients when compared to contemporaneous, matched external controls who solely received SOC (NCT00045968) [68].
Does anyone know what happened to Dr. Bala? He seems to have disappeared and is not listed as a moderator as well.
Then you will be waiting for Godot.
Hoff, your detailed discussion and explanations are much appreciated. I expect they will help reassure and calm a lot of the longs on this board.
Or in the words of Sojo - GUANLB - Going Up And Never Look Back.
Why would a decision such as MTD denial be called Report and Recommendation?
I guess Adam F'Stain has fired the obligatory first shot.
And great to know that Flipper, Hoffman, et al will be staying on and continue to post on this board.
Perhaps because Dr. A is not publishing articles of dubious accuracy about other ground-breaking cancer therapies that have successfully Phase III trials (hmm, I cannot think of any at the moment) without disclosing his conflicts of interest?
Power corrupts and absolute power corrupts absolutely. KG and his group do not care and believe they rule. They are convinced they can do what they are doing for as long as they want.
These several KG videos issued recently are happening because he smells the DOJ and SEC about to knock on his door with an indictment. In recent months, there have been rumors of multiple Wells Notices posted on IHUB . So being the charming fellow he is , KG has decided it’s come time to sell his defense to the public and the regulators, particularly that Citadel never ever had any thoughts of malintent .
Newman, Newman, Newman.😄
Newman, Newman, Newman.😅
If they had included this, you would have been the first to castigate them, as you have in the past, for blaming a contractor.
I suspect the issues identified by the new publisher played a role in the prediction being so far off. I have not seen the date when the original publisher was acquired, but if it happened in June/July, then a review by the acquirer and then alerting NWBO could have easily taken place in August/September. Not knowing the severity of the issues, corrective action could then have happened in the ensuing three months leading to the mid-October PR that essentially indicated that the process was close to completion.
Thermo's previous hint - peanut butter and Jama - was off by about 5 to 6 months, but it did happen.
I recall a team out of the UK that posted negative comments on the JAMA article, with the lead being the head of the organization. Probably another case of one person signing up a bunch of junior colleagues onto the comments.
We can deride them all we want, but the damage has been done. The paper has been out there long enough as a fig leaf for any attacks, raids, continuing bear narratives, etc.🤬 The large donation to Harvard by KG bought a lot of things. Who knows, Reardon may show up next with a named professorship funded by KG.
For years, they used AF to attack NWBO. The strategy has now widened to include insider attacks from the medical community. The next step may be to stage something against the regulators.
Flipper, IMO, there will not be a retraction from the authors because this is intended as a deliberate hit piece. Reardon has long been asking negative leading questions, even as far back as the May NYSA presentation in 2022. Ever since the spoofing lawsuit and Citadel having put AF in the limelight by using his article as cover, I believe he cannot be quite as overt in his attacks. So, I believe they are using Readon et al., and their medical credentials to attack from within the medical community to gain credibility for their attacks. All in my opinion.
It is now established that NWBIO is close (OK, several weeks) to submitting an application to the MHRA. There will then be a longish period while MHRA goes through its process of reviewing, evaluating, and deciding on the MA for DCVAX-L The regulators at MHRA or anywhere else are not going to use the paper for their decision. However, the shorts, adversarial MMs, and their fudster troops need a publicly posted cover for their attacks and stock during this period. Just like the AF article that was used by Citadel in one of its filings to justify its trading attacks, I believe this article, co-authored and posted as an Editor's Choice by an Associate Editor of SNO, is intended to provide that cover during this period.
Birds of a feather, etc.
Does anyone have any information on when the Judge will rule on the MTD?
I think the LSE is far enough and closer to home.
Actually, what was positive is that contrary to previous occasions where they went silent on missing a date, they sent an update on status and stuck their neck out again with a timeline.
Schwab included my NWBO shares held in a rollover IRA account in an email asking me to signup for their SFLP program. Ignored it.
That would be dangerous to their health as they have been using/encouraging those lies for their shorting activities and related profits. In fact, Citadel or one of the defendant MMs used his article as a defense in their filings.